Prosecution Insights
Last updated: April 19, 2026

Examiner: NGUYEN, NGOC-ANH THI

Tech Center 1600 • Art Units: 1615

This examiner grants 33% of resolved cases

Performance Statistics

32.7%
Allow Rate
-27.3% vs TC avg
102
Total Applications
+49.8%
Interview Lift
1286
Avg Prosecution Days
Based on 49 resolved cases, 2023–2026

Rejection Statute Breakdown

1.8%
§101 Eligibility
20.8%
§102 Novelty
55.1%
§103 Obviousness
16.3%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18002385 Chlorite In the Treatment of Acute Respiratory Distress Syndrome Final Rejection The Regents of the University of California
17641124 COMPOSITIONS AND METHODS FOR CANCER TREATMENT BY ENHANCING ANTITUMOR IMMUNITY USING TANNIC ACID-BASED NANOCAPSULES Non-Final OA Purdue Research Foundation
17506242 OIL-BASED COMPOSITION FOR KERATIN FIBERS Final Rejection KAO CORPORATION
17769907 CERAMIDE RATIOS AS PREDICTIVE AND THERAPEUTIC BIOMARKERS FOR LEUKEMIAS Non-Final OA University of Virginia Patent Foundation
17616499 COMPOSITIONS AND METHODS FOR BONE REPAIR AND BONE HEALTH Final Rejection DUKE UNIVERSITY
17779963 DRUG-LOADED IMPLANTED MEDICAL DEVICE AND PREPARATION METHOD THEREFOR Non-Final OA SHANGHAI MICROPORT MEDICAL (GROUP) CO., LTD.
18000491 COMPOSITIONS AND METHODS FOR TREATING A SARS-COV-2 INFECTION Final Rejection THE UNIVERSITY OF HONG KONG
18883477 DRUG AND PRODUCTION METHOD THEREFOR Non-Final OA OSAKA UNIVERSITY
17613783 MONOSACCHARIDE-TAGGED NANO-LIPOSOME DRUG DELIVERY SYSTEM, THE MANUFACTURE AND USE FOR DRUG TARGETING DELIVERY THEREOF Non-Final OA National Yang Ming Chiao Tung University
17911026 METHODS, DEVICES, AND COMPOSITIONS FOR LESION REPAIR AND PREVENTION Non-Final OA UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED
17632131 COSMETIC Final Rejection SHISEIDO COMPANY, LTD.
17433289 TRANSDERMAL PATCH Non-Final OA HISAMITSU PHARMACEUTICAL CO., INC.
17428699 ROTIGOTINE STABILIZATION METHOD Non-Final OA HISAMITSU PHARMACEUTICAL CO., INC.
17759420 INJECTABLE COMPOSITION FOR SKIN AND SOFT TISSUE AUGMENTATION Final Rejection MERZ PHARMA GMBH & CO. KGAA
17632891 PHARMACEUTICAL COMPOSITION COMPRISING ENSIFENTRINE Non-Final OA VERONA PHARMA PLC
17605891 MAGNESIUM ION-CONTAINING MATERIALS AS WHITE PIGMENTS IN ORAL CARE COMPOSITIONS Non-Final OA Omya International AG
18412192 AGRICULTURAL ADMIXTURES Non-Final OA CALIFORNIA SAFE SOIL, LLC
18537353 Synergistic Combinations for Reducing Volatility of Auxin Herbicides Non-Final OA Ethox Chemicals, LLC
18561642 Agricultural Chemical Formulation Non-Final OA Aaron Eberle
17687179 LIQUID HERBICIDAL COMPOSITIONS Non-Final OA UPL LTD
17753890 NANOFIBER- AND NANOWHISKER-BASED TRANSFECTION PLATFORMS Non-Final OA NANOFIBER SOLUTIONS, LLC
18246533 PREPARATION AND STORAGE OF LIPOSOMAL RNA FORMULATIONS SUITABLE FOR THERAPY Final Rejection BioNTech SE
18234230 CARRIER FOR SUSTAINED-RELEASE OF DRUG AND USE THEREOF Final Rejection KUNMING QINGCHENG HEALTHCARE TECH LTD.
17640918 PANCREATIN MICROCAPSULES Non-Final OA AVVA PHARMACEUTICALS LTD.
18347965 COMPOSITION AND METHODS FOR MANAGING AND CONTROLLING HEMIPTERA INSECTS Non-Final OA ISCA Technologies, Inc.
18063460 STABLE COMPOSITIONS OF VARENICLINE Final Rejection MANKIND PHARMA LTD.
18247962 STABILIZATION OF ANTIGENS FOR LONG TERM ADMINISTRATION IN TRANSDERMAL MICRONEEDLE PATCHES Non-Final OA EASTERN VIRGINIA MEDICAL SCHOOL
18023564 LIPID NANOPARTICLE COMPOSITIONS AND METHODS OF USE THEREOF Non-Final OA Cureport Inc.
17948550 OPHTHALMIC PHARMACEUTICAL COMPOSITIONS OF ROFLUMILAST Final Rejection Iolyx Therapeutics, Inc.
17891061 TREATMENT OF OPHTHALMOLOGICAL CONDITIONS WITH ACETYLCHOLINESTERASE INHIBITORS Non-Final OA ATTILLAPS HOLDINGS INC.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month